Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a clinical-stage biotechnology company focused on therapies for immune-mediated and metabolic diseases, with a particular emphasis on ophthalmology and rare retinal conditions. News about Aldeyra often centers on the progress of its RASP (reactive aldehyde species) modulator platform and its late-stage product candidates reproxalap and ADX-2191.
Investors following ALDX news can expect regular updates on regulatory milestones, such as the U.S. Food and Drug Administration’s review of the New Drug Application for topical ocular reproxalap in dry eye disease, extensions of Prescription Drug User Fee Act (PDUFA) target action dates, and feedback on proposed labeling. Aldeyra also reports on orphan drug and fast track designations from the FDA and the European Medicines Agency for ADX-2191 in primary vitreoretinal lymphoma, retinitis pigmentosa, and related inherited retinal dystrophies.
The company’s news flow includes clinical trial readouts and pipeline updates, such as Phase 2 data for ADX-629 in alcohol-associated hepatitis, preclinical results for ADX-248 in models of central nervous system diseases associated with inflammation, and decisions to prioritize next-generation RASP modulators ADX-248 and ADX-246. Aldeyra also issues releases about Special Protocol Assessment agreements, manufacturing inspections and outcomes, and participation in healthcare and ophthalmology conferences and research and development webcasts.
This ALDX news page aggregates these company communications so readers can track developments in Aldeyra’s RASP platform, ophthalmic programs, and broader immune-mediated disease pipeline over time. For investors and observers, the news stream provides context on clinical progress, regulatory interactions, and strategic pipeline decisions that shape the company’s future prospects.
Aldeyra Therapeutics, Inc. (ALDX) will host a conference call on May 5, 2022, at 8:00 a.m. ET to discuss its financial results for Q1 2022, ending March 31, 2022. The call can be accessed via dial-in numbers for both domestic and international callers, with an access code provided. A live audio webcast will be available on Aldeyra's website, and the archived event will remain accessible for 90 days. Aldeyra focuses on therapies for immune-mediated diseases and has several clinical candidates in various stages, including reproxalap and ADX-629.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has announced the presentation of results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial of reproxalap for dry eye disease at the 2022 ASCRS Annual Meeting on April 23, 2022. Reproxalap is a first-in-class small-molecule modulator targeting reactive aldehyde species, currently in Phase 3 development. The company aims to provide innovative therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis, significant markets in ophthalmology.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced the completion of enrollment in the Phase 3 TRANQUILITY-2 Trial for its investigational drug, reproxalap, aimed at treating dry eye disease. The multi-center study enrolled 361 patients and measured tear volume and ocular redness as primary endpoints. Top-line results are expected this quarter, and if successful, the data could support a New Drug Application (NDA) submission. Aldeyra plans to utilize data from completed clinical trials to meet FDA regulatory requirements.
Aldeyra Therapeutics announced promising signs of clinical activity for ADX-629 in three Phase 2 trials aimed at immune-mediated diseases. No safety issues were reported, and the company plans to expand ADX-629's development into new indications, including ethanol toxicity and chronic cough. Key results showed significant decreases in inflammation-related metrics in psoriasis, asthma, and COVID-19 patients. The company will present additional findings and plans during its R&D Day and expects to initiate new trials in 2023.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will hold a Research & Development Day on March 29, 2022, from 10:00 a.m. to 12:30 p.m. ET in New York City. The event will reveal top-line data from Phase 2 clinical trials of ADX-629, a first-in-class orally administered RASP modulator, targeting three inflammatory diseases. Presentations will feature Aldeyra's senior leadership and Dr. Geoffrey M. Thiele from the University of Nebraska Medical Center. A live webcast will be available on their website, with replays for 90 days.
Aldeyra Therapeutics (ALDX) reported its financial results for 2021, highlighting a net loss of $57.8 million, or $1.07 per share, compared to $37.6 million, or $1.11 per share in 2020. The increase in loss is attributed to higher costs in clinical trials and R&D, totaling $44.9 million. As of December 31, 2021, cash and cash equivalents stood at $229.8 million, projected to support operations through 2023. Upcoming milestones include top-line data from ADX-629 trials by March 2022 and results from various Phase 3 trials for reproxalap and ADX-2191 expected throughout 2022.
Aldeyra Therapeutics (Nasdaq: ALDX) announced that its CEO, Todd C. Brady, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference conducted virtually from March 15-17, 2022. The discussion with analyst Justin Kim is set for 11:20 a.m. ET on March 16, 2022, and will be accessible via a webcast on Aldeyra's website, where it will remain archived for 90 days. Aldeyra focuses on therapies for immune-mediated diseases, with key products in various clinical trial phases.
Aldeyra Therapeutics (NASDAQ: ALDX) announced a conference call on March 17, 2022, at 8:00 a.m. ET to discuss its financial results for the year ended December 31, 2021, along with recent corporate highlights. The call will be accessible via dial-in and a live webcast on the company’s website. Aldeyra is focused on developing therapies for immune-mediated diseases, with key candidates reproxalap in Phase 3 trials for dry eye disease and ADX-629 in Phase 2 trials for psoriasis and COVID-19. More information is available on their website.
Aldeyra Therapeutics (NASDAQ: ALDX) has initiated a Phase 2 clinical trial for ADX-2191, an investigational drug for treating retinitis pigmentosa (RP), a rare genetic eye disease affecting 82,000-110,000 individuals in the U.S. The trial will evaluate the safety and tolerability of ADX-2191 in eight patients with rhodopsin mutations. Results are expected in the second half of 2022. ADX-2191 has received orphan drug designation from the FDA, which provides various incentives including market exclusivity upon approval.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) will have its President and CEO, Todd C. Brady, M.D., Ph.D., participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference. The discussion, moderated by Marc Goodman from SVB Leerink, will be available on demand starting at 9:20 a.m. ET on February 16, 2022. Interested parties can access the webcast through the Investors & Media section of Aldeyra's website, where it will remain archived for 90 days. Aldeyra focuses on innovative therapies for immune-mediated diseases with drug candidates like reproxalap and ADX-629 in clinical trials.